DrugPatentWatch Database Preview
Fluciclovine f-18 - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for fluciclovine f-18 and what is the scope of freedom to operate?
Fluciclovine f-18
is the generic ingredient in one branded drug marketed by Blue Earth and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fluciclovine f-18 has thirty-nine patent family members in sixteen countries.
One supplier is listed for this compound.
Summary for fluciclovine f-18
| International Patents: | 39 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 6 |
| Clinical Trials: | 18 |
| Patent Applications: | 16 |
| DailyMed Link: | fluciclovine f-18 at DailyMed |
Recent Clinical Trials for fluciclovine f-18
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| James Mountz | Early Phase 1 |
| M.D. Anderson Cancer Center | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
Pharmacology for fluciclovine f-18
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
Synonyms for fluciclovine f-18
| (18F)FACBC |
| (18F)Fluciclovine |
| (18F)Ge-148 |
| (1R,3R)-1-Amino-3(18f)fluorocyclobutane-1-carboxylic acid |
| [18F]FACBC |
| [18F]Fluciclovine |
| 1-amino-3-fluoranylcyclobutane-1-carboxylic acid |
| 222727-39-1 |
| 38R1Q0L1ZE |
| AC1L9P1E |
| AKOS030238192 |
| anti-(18f)FABC |
| Anti-[18F]FACBC |
| anti-1-Amino-3-(18f)fluorocyclobutane-1-carboxylic acid |
| Anti-1-Amino-3-[18F]fluorocyclobutane-1-carboxylic acid |
| AxuminCN FACBCCN Fluciclovine (18F)CN GE 148CN NMK 36 |
| BCP24384 |
| CHEBI:134703 |
| CHEMBL254468 |
| CHEMBL447701 |
| D10860 |
| DB13146 |
| FACBC F-18 |
| Fluciclovine |
| Fluciclovine ((sup 18)F) |
| Fluciclovine ((sup 18)F) [INN] |
| Fluciclovine (18F) |
| Fluciclovine (18F) (INN) |
| Fluciclovine (18F) [INN] |
| Fluciclovine F 18 |
| Fluciclovine F18 [USAN] |
| Ge-148 (18F) |
| Ge-148 F-18 |
| MOLI001120 |
| NMK36 |
| SCHEMBL10017245 |
| SCHEMBL11939897 |
| SCHEMBL11939900 |
| syn-1-Amino-3-[18F]fluorocyclobutane-1-carboxylic acid |
| syn-3-[18F]FACBC |
| UNII-38R1Q0L1ZE |
US Patents and Regulatory Information for fluciclovine f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for fluciclovine f-18
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200800869 | Start Trial |
| Australia | 720738 | Start Trial |
| Taiwan | I371439 | Start Trial |
| European Patent Office | 1978015 | Start Trial |
| South Korea | 20080071146 | Start Trial |
| Australia | 1120497 | Start Trial |
| Norway | 20180010 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.